Institut Merieux
VC Fund
Lyon, France
Institut Merieux is a VC fund in Lyon focused on Biotechnology and Cannabis. Institut Mérieux contributes to serving medicine and public health across the globe. For the fight against infectious diseases and cancer, it imagines and develops new approaches in the fields of diagnostics,
- Total investments:
- 3
- Last investment:
- Lead investor:
- 0%
Last updated:
For AI agents: llms.txt
Industries Institut Merieux invests in
Stages Institut Merieux invests in
Countries Institut Merieux invests in
Contacts
| Name | Phone | Socials | |
|---|---|---|---|
|
Hedi Ben Brahim
|
|||
Marc Bonneville
|
|||
Investment Focus
Industry
- Biotechnology 2 (67%)
- Cannabis 1 (33%)
- Veterinary 1 (33%)
- Health Care 1 (33%)
- Therapeutics 1 (33%)
Stage
- Private Equity 1 (33%)
- Post-IPO Equity 1 (33%)
Country
- France 1 (33%)
- Switzerland 1 (33%)
Team
| Name | Title | Investments | Links | |
|---|---|---|---|---|
|
Hedi Ben Brahim
Vice-President
|
Vice-President | Total investments: 0 | Find email | |
|
Marc Bonneville
Scientific and medical director
|
Scientific and medical director | Total investments: 0 | Find email |
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Ceva Santé Animale
|
Ceva Sante Animale S.A. engages in the research, development, production, and marketing of pharmaceutical products and vaccines for companion and farm animals. They work with welfare and social programmes around the world to bring this vision to life – anywhere their products and know-how can make a difference and with all kinds of partners. FromUganda, working with small-scale livestock owners and vets to stop sleeping sickness in its tracks, to the UK and USA, where they supply the biggest animal welfare charities with Adaptil® collars to help re-home shelter dogs. | Private Equity / Mar 31, 2025 | |
GeNeuro
|
GeNeuro is a biotechnology company that develops therapeutic drugs for diseases associated with the expression of pathogenic proteins of the human endogenous retroviral origin. The company is primarily focused on nervous system diseases such as multiple sclerosis and schizophrenia. Its products include GNbAC1, a therapeutic monoclonal antibody forthe treatment of multiple sclerosis. It also develops diagnostic tests to dose the multiple sclerosis-associated retrovirus-ENV proteins in patients.GeNeuro was founded in 2006 and is based in Plan-Les-Ouates, Switzerland. | $5.4M / Post-IPO Equity / Feb 01, 2024 | |
|
GeNeuro
|
GeNeuro is a biotechnology company that develops therapeutic drugs for diseases associated with the expression of pathogenic proteins of the human endogenous retroviral origin. The company is primarily focused on nervous system diseases such as multiple sclerosis and schizophrenia. Its products include GNbAC1, a therapeutic monoclonal antibody forthe treatment of multiple sclerosis. It also develops diagnostic tests to dose the multiple sclerosis-associated retrovirus-ENV proteins in patients.GeNeuro was founded in 2006 and is based in Plan-Les-Ouates, Switzerland. | $8M / Post-IPO Equity / May 12, 2022 |
Co-Investors
ArchiMed
1 deal together
Continental Grain Company
1 deal together
EMZ Partners
1 deal together
HOPU Investment Management Company
1 deal together
Invesco
1 deal together
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Recommended lists
FAQ
What does Institut Merieux invest in?
Institut Merieux invests primarily in Biotechnology, Cannabis and Veterinary startups, most often at Private Equity and Post-IPO Equity stage. Most of the 3 investments tracked by Shizune back companies in France. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Institut Merieux?
Public channels for Institut Merieux include LinkedIn and the website linked on this profile. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
Who are the partners at Institut Merieux?
The team at Institut Merieux includes Hedi Ben Brahim (Vice-President) and Marc Bonneville (Scientific and medical director). The Team section lists each member with their title, investment count and links.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
